Photo of John W. Kaveney

Partner, Healthcare and Litigation

John provides legal guidance to healthcare sector clients on a broad variety of topics, including Medicare/Medicaid reimbursement issues, corporate compliance, data privacy and cybersecurity concerns, healthcare provider licensure and medical staffing concerns, involuntary commitment laws, and general healthcare regulatory support. He represents a diverse roster of healthcare entities, including for-profit and nonprofit hospitals and health systems, academic medical centers, individual physicians and physician groups, ambulatory surgery centers, ancillary service providers, medical billing companies, skilled nursing and rehabilitation facilities, behavioral health centers and pharmacies.

John advises on Medicaid reimbursement matters before the New Jersey Division of Medical Assistance and Health Services (DMAHS), which administers the state’s Medicaid programs, and handles Medicare reimbursement disputes, both in New Jersey and in numerous other states, before the federal Provider Reimbursement Review Board (PRRB).

In the area of corporate compliance, John supports clients on matters including the implementation of new, and the assessment and improvement of existing, compliance programs. He assists healthcare clients in navigating compliance audits, internal investigations, and governmental investigations related to compliance issues, including potential violations of the federal Stark Law, Anti-Kickback Statute (AKS), and Civil Monetary Penalties law (CMP). He further provides general guidance concerning compliance and regulatory matters under state and federal healthcare laws.

On issues related to information privacy and cybersecurity at the intersection of healthcare law, John assists providers with issues arising under the Health Insurance Portability and Accountability Act (HIPAA) and the Health Information Technology for Economic and Clinical Health Act (HITECH). This includes the implementation and assessment of privacy and security policies and procedures to ensure the proper protection and utilization of protected health information (PHI) both by healthcare providers and the business associates with which they contract. In addition, he represents healthcare clients in investigating, reporting, and remediating information breaches and the liability such breaches create under various information privacy and security laws.

John also counsels healthcare providers with professional licensure issues and advises hospitals and health systems regarding their medical staff bylaws and corresponding policies and procedures, as well as assisting with internal investigations of medical staff members and the corresponding disciplinary process. He further provides legal guidance related to New Jersey’s involuntary commitment laws, and provides representation in civil litigation.

John serves as Editor-In-Chief of Healthcare Perspectives, Greenbaum’s blog covering issues of interest to the healthcare industry.

Results may vary depending on your particular facts and legal circumstances.

Contact information:

jkaveney@greenbaumlaw.com | 973.577.1796 | vCard | LinkedIn

For more information visit the Greenbaum, Rowe, Smith & Davis LLP website.

The American Health Law Association (AHLA) recently published the Third Edition of its popular treatise “Corporate Practice of Medicine: A 50 State Survey.” The publication provides helpful guidance on each state’s corporate practice of medicine (CPOM) doctrine, including discussions of how each state interprets the law when dealing with unlicensed individuals and plenary…

On May 20, 2024, the American Medical Association and more than 100 other organizations issued a joint letter to Health and Human Services (HHS) Secretary Xavier Becerra concerning the February 21, 2024 reported cyber incident involving Change Healthcare. The letter requested clarity from the HHS Office of Civil Rights (OCR) “around reporting responsibilities and [to]…

In August, Governor Murphy signed into law Senate Bill 3929 (approved P.L. 2023, c. 139), which amended the involuntary commitment process and added, among other things, a mechanism by which hospitals could request an additional 72 hours to hold patients when having difficulty locating a short-term care or psychiatric facility, or special psychiatric hospital with…

John W. Kaveney, a partner in the firm’s Healthcare and Litigation Departments, will present the program “The Conclusion of the Public Health Emergencies: What This Means for Healthcare Providers and the Accommodations Put in Place by the Federal and State Governments” at the New Jersey & Metro Philadelphia HFMA 47th Anniversary Annual Institute. The…

During the COVID-19 pandemic, the federal government and many state governments went to great lengths to relax many of the restrictions on telehealth that had historically limited this medium in the provision of healthcare services to patients. However, in an effort to ensure that patients could continue to access necessary healthcare during this time period…

As recently reported by HealthITSecurity, IBM Security’s 2023 Cost of a Data Breach Report revealed that the average cost of a healthcare data breach was almost $11 million in 2022, an $800,000 increase from the prior year and a 53% increase from 2020. The report further revealed that the global average cost of a…

On June 15, 2023, the Medicare Payment Advisory Commission (MedPAC), a nonpartisan independent legislative branch agency that was created to advise Congress on a range of issues affecting Medicare, issued its 2023 Report to Congress. Included therein was a report, mandated by the Consolidated Appropriations Act, on the usage of telehealth services during the public…

In August 2022, President Biden signed into law the Inflation Reduction Act. The Act’s key provisions include the ability of the federal government to negotiate certain prescription drug pricing. Specifically, the law created a program that allows the federal government to negotiate prices for a limited number of high-cost single-source drugs (lacking generic and/or biosimilar…